CTRI/2022/07/044487尚未招募未知
OWER CROSS SYNDROME: SPECIFIC TREATMENT PROTOCOL VERSUS GENERALIZED TREATMENT PROTOCOL - SINGLE RANDOMIZED BLINDED TRIA
Dr Trupti Mehta0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects clinically diagnosed with low back pain with lower crossed syndrome.
- •2. Minimum pain score on NPRS 4/10.
- •3. Subjects with low back pain < 6 months
排除标准
- •1. Subjects diagnosed with lumbar canal stenosis & spondylolisthesis.
- •2. Subjects with recent history of trauma or fall.
- •3. Subjects with neurological deficit.
- •4. Subjects administered corticosteroid injection for pain relief in preceding 3 months.
- •5. Past history of lower limb, hip, pelvis and spine trauma or fracture.
- •6. Subjects with any recent medical or physiotherapy treatment
研究者
相似试验
尚未招募
2 期
HomoeopathyasadjuvantinmanagementofcoronavirusinfectioCTRI/2020/04/024925Bajaj Auto Ltd
已完成
不适用
AYURVEDIC MANAGEMENT IN HYPOTHYROIDISMCTRI/2021/12/038495Pt Khushilal Sharma Government Autonomous Ayurveda College and Institute Bhopal MP38
进行中（未招募）
1 期
AA SU011248 TREATMENT PROTOCOL FOR PATIENTS WITH CYTOKINE- REFRACTORY METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248Histopathologically confirmed renal cell carcinoma with metastasesMedDRA version: 8.0Level: LLTClassification code 10038415EUCTR2005-002097-30-HUPfizer Kft.1,000
进行中（未招募）
1 期
AA SU011248 TREATMENT PROTOCOL FOR PATIENTS WITH CYTOKINE- REFRACTORY METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248EUCTR2005-002097-30-SKPfizer Inc.1,000
进行中（未招募）
不适用
AA SU011248 TREATMENT PROTOCOL FOR PATIENTS WITH CYTOKINE- REFRACTORY METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248 - N/AEUCTR2005-002097-30-PTPfizer Inc.1,000